Tezspire (tezepelumab) has received a positive opinion from the CHMP for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adults. The recommendation supports EU approval of a new option for patients with moderate to severe disease who have not responded to conventional or biologic therapies. The decision is based on results from the phase 3 WAYPOINT trial, which showed Tezspire significantly reduced nasal polyp severity and congestion compared with placebo. At week 52, patients receiving Tezspire saw a mean reduction in Nasal Polyp Score of -2.08 and in Nasal Congestion Score of -1.04. Tezspire is already approved for severe asthma in the US, EU, Japan and over 60 countries.